Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt.

Other

Richter Gedeon Vegyeszeti Gyar Rt

Chinoin, Ltd.

Chinoin Gyogyszer Es Vegyeszeti

Chinoin Pharmaceutical and Chemical Works Ltd.

Mta Kutatasi Eszkozoket Kivitelezo Vallata

Agoston David

Sandor Virag

Zoltan Meszaros

Jozsef Knoll

Istvan Hermecz

Agnes Horvath

Gyula Sebestyen

Peter Szentmiklosi

Sandor Makleit

Rezso Bognar

Zsuzsanna Furst

Gyula Valovics

Csaba Szantay

Lajos Szabo

Attila Mandi

Lelle V Vasvari Nee Debreczy

Gabor Nagy

Istvan Tibor Toth

Laszlo Toke

Erzsebet Kanyo

Gabor Kulcsar

Lelle Vasvari

Tibor Horvath

Sandor J Nagy

Tibor Zilahi

Janos Pogany

Jozsef Szejtli

Laszlo Tardos

Gabor Horvath

Lajos Szente

Katalin Marmarosi Nee Kellner

Istvan Racz

Josef Szejtli

Kalman Simon

Ferenc Kovacs

Jozsef Schawartz

Lelle Vasvari, Nee Debreczy

Csaba Kiss

Maria Hornyak

Kenez Nee DaMarai

Eva Majorszki

Ilona Erdelyi

Laszlo Szavik

Eva Dosa

Edomer Tassonyi

Zsuzsanna Nagy Nee Biro

Agnes Udvardi

Ilona Simonidesz Nee Vermes

Istvan Hermes

Agnes Udvardy

Laszlo Ronkos

Laszlo Szlavik

Process for measuring and determining zeta-potential in a laminarly

A process and apparatus for measuring the flow rate of solid granular material in which a sample holder of variable geometry is provided with an aperture containing a shutter. The aperture is opened and the material is collected and weighed. Either the time to collect a given weight or the weight collected in a given time is determined and combined with signals representing the sample holder geometry, aperture cross section and material constants to provide a measure of flow rate.

Process and apparatus for determining and influencing the flow

This invention relates to a process and an apparatus for producing tablets of good quality with minimal waste by compressing granulated matter at a regulated temperature. An important advantage of the invention is that it permits direct tabletting of active ingredients without the need to include additives in the tablets.

Process for tablet production

This invention relates to new synergistic antimicrobial compositions containing primycin, doxycycline and sisomicin.

Synergistic antimicrobial compositions

New compounds of the following formula are disclosed:

Condensed pyrimidines

Antiphlogistic and anticoagulant compounds of the formula: ##STR1## wherein m is 0, 1 or 2,

New optionally racemic or optically active pyrimido(1,2a) heterocyclic compounds of the formula ##STR1## wherein m is 0, 1 or 2,

Antiphlogistic and anticoagulant condensed pyrimidine derivatives

Time-release pharmaceutical compositions, suitable for oral administration, are disclosed, which comprise as active ingredient 50 to 70% by weight of a compound of the formula (I) ##STR1## or the formula (Ia) ##STR2## wherein R is hydrogen or --CH.sub.2 COOH,

Time-release

A synergistic antimicrobial active ingredient for a pharmaceutical or veterinary composition comprises 5 to 50 percent by weight of a primycin component which consists of a primycin fermentation product of Thermonospora galeriensis and 95 to 50 percent by weight of at least one other component selected from the group which consists of doxycyline compounds and sisomicin compounds. The doxycycline compounds are selected from the group which consists of doxycycline, salts thereof with mineral acids, and doxycycline tryclate. The sisomicin compounds are selected from the group which consists of sisomicin, substituted sisomicins with substitution at the N atom by lower alkyl, hydroxyl lower alkyl, lower aminoalkyl and lower alkanoyl, and sisomicin acid salts.

An antiphlogistic compound of the formula (I) ##STR1## or a pharmaceutically effective salt thereof wherein R.sup.1 and R.sup.2 are hydrogen or C.sub.1-4 alkoxy or together form a methylenedioxy group;

Benzo(a)quinolizidine derivatives

The invention relates to stabilized, prostaglandin-containing tablets with controlled rate of solubility, for local use and a process for the preparation thereof. The tablets according to the invention comprise 0.2 to 20% by weight of one or more natural or synthetic prostaglandins, 0.4 to 40% by weight of a non-toxic buffer, which adjusts the pH of the liquid film formed on the surface of the solid phase due to air humidity, to 3 to 5, 1 to 50% by weight of stearic acid, 0 to 15% by weight of an alkali earth metal stearate, 10 to 95% by weight of lactose and/or mannite, 0 to 15% by weight of a further granulation aid, 1 to 30% by weight of a disintegrating agent and optionally 0.5 to 10% by weight of a flavoring and aroma substance and are prepared under a pressure of 500 to 2000 kp./cm.sup.2. (49.03 to 196.13 MPa).

Stabilized, prostaglandin-containing tablets with controlled rate of

An optically active or racemic fused pyrimidine derivative of the formula I ##STR1## has pharmaceutical activity in decreasing serum lipids, cholesterol deposits and, in general, against atherosclerosis.

Fused pyrimidine derivatives and antiatherosclerotic methods of

The invention relates to an inclusion complex of 1-(p-chloro-benzoyl)-5-methoxy-2-methyl-indol-3-yl-acetic acid (indomethacin) and cyclodextrin of a molar ratio of about 2:1. The inclusion complex can be prepared by reacting about 2 moles of alpha or beta cyclodextrin with about 1 mole of 1-(p-chloro-benzoyl)-5-methoxy-2-methyl-indol-3-yl-acetic acid under heating in the presence of an organic solvent which dissolves indomethacin and does not form a stable complex with cyclodextrin. The new complex is at least as active antiinflammatory agent as indomethacin and at the same time shows substantially less ulcerative side-effect.

Inclusion complex of cyclodextrin and indomethacin and a process for the

2-oxo-3-(.beta.-cyanoethyl)-9,10-methylenedioxy-1,2,3,4,6,7-hexahydro-11bH- benzo(a)quinolizidine (SC-118) especially and the corresponding 9,10-diethoxy compound are superior antiphlogistics which are used in effective amounts in antiphlogistic therapy.

Antiphlogistic method of treatment

Compounds of the formula: ##STR1## or pharmaceutically acceptable salts thereof are disclosed wherein R is hydrogen or C.sub.1 to C.sub.6 alkyl;

Fused pyrimidine derivatives and compositions for treating

Growing community of inventors

Budapest, Hungary

Agoston David